ATE483716T1 - Lösungsmittelfreies amorphes rapamycin - Google Patents

Lösungsmittelfreies amorphes rapamycin

Info

Publication number
ATE483716T1
ATE483716T1 AT05792296T AT05792296T ATE483716T1 AT E483716 T1 ATE483716 T1 AT E483716T1 AT 05792296 T AT05792296 T AT 05792296T AT 05792296 T AT05792296 T AT 05792296T AT E483716 T1 ATE483716 T1 AT E483716T1
Authority
AT
Austria
Prior art keywords
free
solvent
amorphic
rapamycin
therapeutic agents
Prior art date
Application number
AT05792296T
Other languages
English (en)
Inventor
Cynthia A Maryanoff
Karel Six
Roger Vandecruys
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Application granted granted Critical
Publication of ATE483716T1 publication Critical patent/ATE483716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05792296T 2004-08-27 2005-08-24 Lösungsmittelfreies amorphes rapamycin ATE483716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60532404P 2004-08-27 2004-08-27
PCT/US2005/030606 WO2006026531A1 (en) 2004-08-27 2005-08-24 Solvent free amorphous rapamycin

Publications (1)

Publication Number Publication Date
ATE483716T1 true ATE483716T1 (de) 2010-10-15

Family

ID=35539393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05792296T ATE483716T1 (de) 2004-08-27 2005-08-24 Lösungsmittelfreies amorphes rapamycin

Country Status (7)

Country Link
US (2) US7393952B2 (de)
EP (1) EP1781672B1 (de)
JP (1) JP5117190B2 (de)
AT (1) ATE483716T1 (de)
CA (1) CA2578245C (de)
DE (1) DE602005024012D1 (de)
WO (1) WO2006026531A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715771B2 (en) * 2003-02-26 2014-05-06 Abbott Cardiovascular Systems Inc. Coated stent and method of making the same
US7255891B1 (en) * 2003-02-26 2007-08-14 Advanced Cardiovascular Systems, Inc. Method for coating implantable medical devices
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20090011117A1 (en) * 2007-07-03 2009-01-08 Endotronix, Inc. Methods for texturing a surface of an endovascular implant
EP2676687A1 (de) 2008-06-25 2013-12-25 Boston Scientific Scimed, Inc. Medizinische Vorrichtungen mit therapeutischen Mitteln
IT1400977B1 (it) 2010-07-01 2013-07-05 Euticals Spa Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
JP6472155B2 (ja) * 2013-04-01 2019-02-20 テルモ株式会社 ステントおよびステントデリバリーシステム
WO2015181826A1 (en) 2014-05-27 2015-12-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Crystalline coating and release of bioactive agents
WO2017048989A1 (en) 2015-09-15 2017-03-23 Fong Kenton D Devices and methods for anchoring a sheath in a tissue cavity
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
CN108129490B (zh) * 2017-12-11 2020-12-01 成都海创药业有限公司 一种制备依维莫司无定形固体的方法
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6384213B1 (en) 1998-10-23 2002-05-07 Ranbaxy Laboratories Limited Process for preparing a pure, pharmacopoeial grade amorphous form of cefuroxime axetil
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
KR100995225B1 (ko) * 2002-04-22 2010-11-17 재단법인 이쯔우 연구소 혈관성 질환의 치료를 위한 의약
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CA2499594A1 (en) * 2002-09-20 2004-04-01 Conor Medsystems, Inc. Expandable medical device with openings for delivery of multiple beneficial agents
US20040093064A1 (en) * 2002-11-12 2004-05-13 Gjalt Bosma Drug eluting stent graft combination
JP2007500191A (ja) 2003-07-25 2007-01-11 ワイス Ｃｃｉ−７７９の凍結乾燥処方
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DE602005024012D1 (de) 2010-11-18
CA2578245C (en) 2013-10-29
EP1781672B1 (de) 2010-10-06
US20060128739A1 (en) 2006-06-15
JP5117190B2 (ja) 2013-01-09
JP2008511642A (ja) 2008-04-17
CA2578245A1 (en) 2006-03-09
EP1781672A1 (de) 2007-05-09
US20080227982A1 (en) 2008-09-18
WO2006026531A1 (en) 2006-03-09
US7393952B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
ATE483716T1 (de) Lösungsmittelfreies amorphes rapamycin
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
TW200738725A (en) Unsaturated mTOR inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
CR8744A (es) Compuestos terapeuticos
IL177483A0 (en) Means for transdermal administration of nicotine
TW200801006A (en) Fused bicyclic mTOR inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
UY29246A1 (es) Nuevos compuestos
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
BRPI0415164A (pt) dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador
GB0416508D0 (en) Therapeutic agents
NO20072832L (no) Smertestillende middel
EA200700766A1 (ru) Способ получения производных [1,4,5]-оксадиазепина
MX2010006019A (es) Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.
MX2010001303A (es) Compuestos terapeuticos.
MX2008010804A (es) Derivados de rapamicina para tratar neuroblastoma.
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
DK1865931T3 (da) Transdermal plaster
GB0410238D0 (en) Therapeutic agents
MY140538A (en) Substituted n-acyl-2-aminothiazoles
BRPI0414873A (pt) derivados de imidazopiridina como inibidores de no-sintase induzìveis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties